Type 2 Diabetes, Metabolic Syndrome, and Lipid Metabolism
January 2014
in “
S. Karger AG eBooks
”
New to Hydrocortisone? There is a guide in the encyclopedia. Read the guide → 
Studysummary Type 2 diabetes in youth is increasing, with high treatment failure rates and more severe than Type 1; certain drugs can lower lipid levels effectively with varying side effects, and apples may benefit heart health like statins but with fewer side effects. Our plain-language summary of this paper — not a Tressless recommendation.
The document from 2014 discusses the prevalence, risks, and management of Type 2 Diabetes Mellitus (T2DM) in youth, with a study indicating a 0.36% prevalence among adolescents in the USA and a high rate of undiagnosed cases. The TODAY clinical trial with 699 obese 10- to 17-year-olds showed that while treatments like metformin plus rosiglitazone were safe, there was a high rate of treatment failure. T2DM was found to be more hazardous and lethal compared to Type 1 Diabetes Mellitus (T1DM), with higher mortality rates and complications. The document also explores the role of metformin in lifespan extension, a mutation in DYRK1B associated with Metabolic Syndrome (MetS), and the relationship between cortisol levels in hair and MetS. A study on prolactin levels in obese children suggested that prolactin could be a metabolic risk marker, with lifestyle interventions improving metabolic parameters. The document also reviews the 2013 ACC/AHA cholesterol guidelines, which recommend wider statin use, and the impact of mipomersen and evolocumab as lipid-lowering therapies. Mipomersen showed significant lipid reduction but had a high dropout rate due to side effects, while evolocumab was effective in reducing LDL-C levels with a low incidence of adverse events. Lastly, a humorous modeling study compared the effects of a statin a day to an apple a day on vascular mortality, suggesting that apples might offer similar benefits with fewer side effects.
